Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of “Buy” from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $25.20.

ATXS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday. TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday. Finally, Oppenheimer increased their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday.

Institutional Investors Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. AJOVista LLC bought a new stake in Astria Therapeutics during the fourth quarter valued at $51,000. Vivo Capital LLC boosted its holdings in shares of Astria Therapeutics by 47.7% in the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after buying an additional 801,528 shares during the period. Panagora Asset Management Inc. bought a new stake in shares of Astria Therapeutics during the 4th quarter valued at about $119,000. Trexquant Investment LP bought a new stake in shares of Astria Therapeutics during the 4th quarter valued at about $409,000. Finally, Affinity Asset Advisors LLC raised its stake in Astria Therapeutics by 46.6% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock worth $11,262,000 after acquiring an additional 466,165 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $11.06 on Friday. The business’s 50-day simple moving average is $10.12 and its 200 day simple moving average is $11.37. The company has a market cap of $607.34 million, a P/E ratio of -4.77 and a beta of 0.73. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Analysts predict that Astria Therapeutics will post -1.62 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.